Skip to main content
. 2009 Nov 26;13(8b):2189–2199. doi: 10.1111/j.1582-4934.2008.00673.x

Figure 6.

Figure 6

The effects of strontium ranelate (SrRan) in osteoblasts involve prostaglandins. (A, B) Osteoblasts from [CaSR+/+] and [CaSR−/−] mice were treated with SrRan (3 mM) for 24 hrs in the presence of the COX‐2 inhibitor NS‐398 (0.1 μM) or the solvent, cells were pulsed with BrdU and processed by ELISA to determine BrdU incorporation. Results are expressed as treated over control ratio (T/C) (mean ± SD; n= 6). a and b indicate a significant difference with untreated and SrRan‐treated cells, respectively (P < 0.05). (C, D) Osteoblasts from [CaSR+/+] and [CaSR−/−] mice were cultured in DMEM supplemented with 5% FCS (control) or 1% FCS for 24 hrs and treated with SrRan (3 mM) for 24 hrs in the presence of the COX‐2 inhibitor NS‐398 (0.1 μM) or the solvent, and cell apoptosis was evaluated by the Apopercentage assay. Results are expressed as treated over control ratio (T/C) (mean ± SD; n= 6). a, b and c indicate a significant difference with the 10% FCS, 1% FCS and SrRan‐treated groups, respectively (P < 0.05).